센세이 바이오테라퓨틱스(SNSE)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $28.55 (-2.83%), 시가총액 $0.02B, 52주 범위 $0.29 ~ $35.07.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known a
센세이 바이오테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
센세이 바이오테라퓨틱스의 현재 주가는 $28.55 (-2.83%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
센세이 바이오테라퓨틱스의 시가총액은 약 $0.02B입니다.
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-